The FDA has granted Philip Morris the authority to market its ZYN nicotine pouches as a less harmful option compared to traditional cigarettes. This approval, which encompasses 20 variants of ZYN products, allows Philip Morris to advertise these pouches as lower risk for cancer and other health issues associated with smoking. Despite the potential benefits highlighted, concerns regarding youth usage remain prevalent as the FDA authorizes flavored options. This significant move by the FDA may reshape perceptions of nicotine products in the context of harm reduction.